LLY

974.86

+5.69%↑

JNJ

186.4

+0.06%↑

UNH

322.57

-0.48%↓

NVS

127.08

+0.63%↑

ABT

125.54

-0.52%↓

LLY

974.86

+5.69%↑

JNJ

186.4

+0.06%↑

UNH

322.57

-0.48%↓

NVS

127.08

+0.63%↑

ABT

125.54

-0.52%↓

LLY

974.86

+5.69%↑

JNJ

186.4

+0.06%↑

UNH

322.57

-0.48%↓

NVS

127.08

+0.63%↑

ABT

125.54

-0.52%↓

LLY

974.86

+5.69%↑

JNJ

186.4

+0.06%↑

UNH

322.57

-0.48%↓

NVS

127.08

+0.63%↑

ABT

125.54

-0.52%↓

LLY

974.86

+5.69%↑

JNJ

186.4

+0.06%↑

UNH

322.57

-0.48%↓

NVS

127.08

+0.63%↑

ABT

125.54

-0.52%↓

Search

Repligen Corp

Открыт

СекторЗдравоохранение

148.94 4.52

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

142.5

Макс.

150.01

Ключевые показатели

By Trading Economics

Доход

9M

15M

Продажи

6.4M

189M

P/E

Средняя по отрасли

7,508.5

77.256

Прибыль на акцию

0.46

Рентабельность продаж

8.152

Сотрудники

1,778

EBITDA

-98M

-54M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+28.39% upside

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-909M

8.4B

Предыдущая цена открытия

144.42

Предыдущая цена закрытия

148.94

Новостные настроения

By Acuity

50%

50%

161 / 374 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Strong Bearish Evidence

Repligen Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

9 нояб. 2025 г., 21:36 UTC

Отчет

Australia's ANZ Bank Posts 10% Drop in Annual Profit -- Update

9 нояб. 2025 г., 21:22 UTC

Отчет

Australia's ANZ Bank Posts 10% Drop in Annual Profit

10 нояб. 2025 г., 00:00 UTC

Обсуждения рынка

India Inflation Poised to Hit New Low -- Market Talk

9 нояб. 2025 г., 23:47 UTC

Обсуждения рынка

Nikkei May Rise on Weaker Yen, Earnings Hopes -- Market Talk

9 нояб. 2025 г., 23:35 UTC

Обсуждения рынка

Gold Edges Higher Amid Signs of U.S. Economic Weakness -- Market Talk

9 нояб. 2025 г., 21:05 UTC

Отчет

ANZ FY Total Operating Expenses A$12.88B Vs. A$11.465B Pro Forma>ANZ.AU

9 нояб. 2025 г., 21:04 UTC

Отчет

ANZ FY Operating Expenses A$11.85B Ex-Significant Items>ANZ.AU

9 нояб. 2025 г., 21:03 UTC

Отчет

ANZ 2H Net Interest Margin 1.54% Vs. 1.56% in 1H>ANZ.AU

9 нояб. 2025 г., 20:49 UTC

Отчет

ANZ FY Australia Retail Deposits Up 6% on Year>ANZ.AU

9 нояб. 2025 г., 20:49 UTC

Отчет

ANZ FY Australia Home Loan Lending Up 5% on Year>ANZ.AU

9 нояб. 2025 г., 20:45 UTC

Отчет

ANZ FY Average Customer Deposits A$760.8B Vs. A$669.4B>ANZ.AU

9 нояб. 2025 г., 20:45 UTC

Отчет

ANZ FY Average Gross Loans & Advances A$833.6B Vs. A$733.8B>ANZ.AU

9 нояб. 2025 г., 20:42 UTC

Отчет

ANZ FY Results Include Full-Year Benefit of Suncorp Bank Acquisition>ANZ.AU

9 нояб. 2025 г., 20:42 UTC

Отчет

ANZ FY Net Interest Margin 1.55% Vs. 1.57%>ANZ.AU

9 нояб. 2025 г., 20:41 UTC

Отчет

ANZ FY Common Equity Tier 1 Ratio 12.0% Vs. 12.2%>ANZ.AU

9 нояб. 2025 г., 20:41 UTC

Отчет

ANZ FY Net Profit Includes A$1.11B of Notable Items>ANZ.AU

9 нояб. 2025 г., 20:39 UTC

Отчет

ANZ FY Credit Impairment Charge A$441M Vs. A$406M>ANZ.AU

9 нояб. 2025 г., 20:39 UTC

Отчет

ANZ FY Rev A$22.19B Vs. A$20.55B >ANZ.AU

9 нояб. 2025 г., 20:38 UTC

Отчет

ANZ Keeps Dividend at A$0.83 >ANZ.AU

9 нояб. 2025 г., 20:38 UTC

Отчет

ANZ FY Cash Profit A$5.79B Vs. A$6.725B>ANZ.AU

9 нояб. 2025 г., 20:38 UTC

Отчет

ANZ FY Net A$5.89B Vs. Net A$6.535B >ANZ.AU

8 нояб. 2025 г., 13:10 UTC

Приобретения, слияния, поглощения

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- Update

8 нояб. 2025 г., 03:50 UTC

Приобретения, слияния, поглощения

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- 4th Update

8 нояб. 2025 г., 03:41 UTC

Приобретения, слияния, поглощения

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- WSJ

8 нояб. 2025 г., 03:07 UTC

Приобретения, слияния, поглощения

Pfizer and Metsera Reach Deal Worth Up to $10 Billion -- WSJ

7 нояб. 2025 г., 22:36 UTC

Отчет

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7 нояб. 2025 г., 22:22 UTC

Отчет

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7 нояб. 2025 г., 22:03 UTC

Отчет

Constellation Software 3Q Rev $2.95B >CSU.T

7 нояб. 2025 г., 22:03 UTC

Отчет

Constellation Software 3Q Net $210M >CSU.T

7 нояб. 2025 г., 22:03 UTC

Отчет

Constellation Software 3Q EPS $9.89 >CSU.T

Сравнение c конкурентами

Изменение цены

Repligen Corp Прогноз

Целевая цена

By TipRanks

28.39% рост

Прогноз на 12 месяцев

Средняя 183.36 USD  28.39%

Максимум 220 USD

Минимум 135 USD

Основано на мнении 15 аналитиков Wall Street, спрогнозировавших целевые цены для Repligen Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

15 ratings

11

Покупка

4

Удержание

0

Продажа

Техническая оценка

By Trading Central

125.31 / 140.7Поддержка и Сопротивление

Краткосрочная

Strong Bearish Evidence

Среднесрочная

Strong Bearish Evidence

Долгосрочная

Strong Bearish Evidence

Настроения

By Acuity

161 / 374Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Repligen Corp

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
help-icon Live chat